Table 1.
Comparison of different studies on urinary angiogenin (ANG) as a diagnostic biomarker in bladder cancer.
| Author/year | Country | Case | Control | AUC | Sensitivity | Specificity | PPV | NPV | Accuracy | Cut-off | Detection method |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Eissa/2004 | Egypt | 63 | 46 | 0.775 | 75.4% | 70.3% | 84.9% | 80.0% | 81.2% | 322.7 ng/mg | ELISA |
| Eissa/2009 | Egypt | 240 | 110 | 0.77 | 75.2% | 69.5% | NR | NR | NR | 425.0 pg/mg | ELISA |
| Shabayek/2014 | Egypt | 50 | 20 | 0.803 | 66.0% | 75.0% | 76.74% | 63.82% | NR | 145.0 pg/ml | ELISA |
| Urquidi/2012 | USA | 64 | 63 | 0.857 | 67.0% | 97.0% | 96.0% | 74.0% | 86.0% | 410.9 pg/ml | ELISA |
BCa: bladder cancer; AUC: area under the curve; PPV: positive predictive value; NPV: negative predictive value; NR: not reported; ELISA: enzyme-linked immunosorbent assay.